IWM
DNA icon

IHT Wealth Management’s Ginkgo Bioworks DNA Stock Holding History

IHT Wealth Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-371
Closed -$4.95K – 1154
2024
Q2 		$4.95K Sell
371
-1,528
-80% -$45.6K ﹤0.01% 1022
2024
Q1 		$88.1K Buy
1,899
+12
+0.6% +$621 ﹤0.01% 976
2023
Q4 		$128K Sell
1,887
-17
-0.9% -$1.04K 0.01% 938
2023
Q3 		$138K Buy
1,904
+11
+0.6% +$879 0.01% 906
2023
Q2 		$141K Buy
1,893
+581
+44% +$34.4K 0.01% 911
2023
Q1 		$69.8K Buy
1,312
+100
+8% +$6.34K ﹤0.01% 917
2022
Q4 		$82K Sell
1,212
-82
-6% -$7.54K 0.01% 871
2022
Q3 		$161K Buy
1,294
+132
+11% +$15.7K 0.01% 797
2022
Q2 		$111K Buy
+1,162
New +$142K 0.01% 694
2022
Q1 		– Sell
-275
Closed -$91K – 793
2021
Q4 		$91K Buy
+275
New +$131K 0.01% 780

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IHT Wealth Management's DNA Position: Q3 2024 in Review

IHT Wealth Management sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 371 shares — an estimated $4.95K sold.

IHT Wealth Management first reported a position in DNA in Q4 2021 and held it in 10 quarters. The position peaked at $161K in Q3 2022. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • IHT Wealth Management reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • IHT Wealth Management sold 371 Ginkgo Bioworks shares in Q3 2024, an estimated $4.95K.
  • IHT Wealth Management first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 10 quarters.
  • IHT Wealth Management's Ginkgo Bioworks position peaked at $161K in Q3 2022.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on IHT Wealth Management's 13F filing for Q3 2024, filed 14 Nov 2024.